ONO-1301增强体外成骨细胞分化及体内骨形态发生蛋白诱导的骨形成
本研究通过体外实验和体内小鼠异位模型及大鼠脊柱融合原位模型,评估前列环素激动剂ONO-1301对骨形态发生蛋白(BMP)诱导的成骨细胞分化和骨形成的影响。结果显示ONO-1301可显著增加碱性磷酸酶活性,并显著增加BMP诱导的异位骨体积及脊柱融合的骨体积和融合率。作者认为ONO-1301有潜力作为BMP诱导骨形成的增强剂用于临床。
要点
- ONO-1301显著增加原代成骨细胞和ST2细胞的碱性磷酸酶活性。
- ONO-1301与rhBMP-2共处理显著增加原代成骨细胞、ST2和MC3T3-E1细胞的碱性磷酸酶活性。
- ONO-1301显著增加小鼠异位模型BMP诱导的骨体积及大鼠脊柱融合模型的骨体积和融合率。
核心结论
- 本研究证明前列环素IP激动剂ONO-1301改善体外BMP-2诱导的成骨细胞分化以及体内异位和原位骨形成。
- 结果提示ONO-1301有潜力作为BMP诱导骨形成的增强剂用于临床。
研究设计与样本
- 体外实验使用小鼠原代成骨细胞及细胞系(ST2、MC3T3-E1、C2C12、CH310T1/2),采用碱性磷酸酶(ALP)和WST-1法检测ONO-1301(伴或不伴重组人BMP-2)对成骨细胞分化和细胞增殖的影响。
- 体内实验采用小鼠肌肉袋移植模型(异位模型)和大鼠脊柱融合模型(原位模型),评估ONO-1301对rhBMP-2诱导骨形成的影响。
主要发现
- ONO-1301显著增加原代成骨细胞和ST2细胞的ALP活性。
- ONO-1301与rhBMP-2共处理显著增加原代成骨细胞、ST2和MC3T3-E1细胞的ALP活性。
- ONO-1301和ONO-1301联合rhBMP-2均不影响细胞增殖。
- 在异位模型中,ONO-1301显著增加BMP诱导的异位骨体积。
- 在原位模型中,ONO-1301显著增加骨体积和融合率。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY DESIGN: In vitro and in vivo assessment of osteogenic effect by prostacyclin agonist (ONO-1301). OBJECTIVE: The aim of this study was to investigate the effects of ONO-1301 on in vitro osteoblastic differentiation and in vivo bone formation induced by bone morphogenetic protein (BMP). SUMMARY OF BACKGROUND DATA: Among prostaglandins (PGs), PGE2 is the most abundant in bone tissue and its effects on bone formation have been well studied. PGI2 (prostacyclin) is the second most abundant PG in bone tissue and plays important roles in hemodynamics. However, the effects of PGI2 on osteoblast differentiation and bone regeneration have not been elucidated. METHODS: The effects of PGI2 agonist (ONO-1301), with and without recombinant human (rh) BMP-2, on osteoblastic differentiation and cell proliferation were investigated in vitro using alkaline phosphatase (ALP) and WST-1 assays. Murine primary osteoblasts and cell lines (ST2, MC3T3-E1, C2C12, and CH310T1/2) were used for the study. The effects of ONO-1301 on rhBMP-2 induced bone formation were investigated in a mouse model of muscle pouch transplantation (ectopic model) and in a rat model of spinal fusion (orthotopic model). RESULTS: ONO-1301 significantly increased ALP activity in the primary osteoblasts and ST2 cells. In addition, cotreatment with ONO-1301 and rhBMP-2 significantly increased ALP activity in the primary osteoblasts, as well as in ST2 and MC3T3-E1 cells. Cell proliferation was not affected by both ONO-1301 and ONO-1301 as well as rhBMP-2. In the ectopic model, ONO-1301 significantly increased the volume of ectopic bone whose formation was induced by BMP. In addition, in the orthotopic model, ONO-1301 significantly increased bone volume and fusion rate. CONCLUSION: This study has demonstrated that the PG IP agonist ONO-1301 improves in vitro BMP-2 induced osteoblast differentiation and in vivo ectopic and orthotopic bone formation. The results suggest that ONO-1301 has a potential clinical application as an enhancer of BMP-induced bone formation. LEVEL OF EVIDENCE: N/A.
引用
- Kanayama S, Kaito T, Kitaguchi K, et al. ONO-1301 Enhances in vitro Osteoblast Differentiation and in vivo Bone Formation Induced by Bone Morphogenetic Protein. Spine (Phila Pa 1976). 2018. PMID: 29016438. doi:10.1097/BRS.0000000000002439
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。